Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 678 across all filing types
Latest filing 2023-11-08 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges informing about the conclusion of a US FDA inspection at a specific company facility. It references a previous intimation and states that the Establishment Inspection Report (EIR) has been received, indicating closure of the inspection. The document is brief (1395 characters) and serves as an announcement of an event related to regulatory compliance rather than a detailed report or financial filing. There is no financial data, no detailed audit or management discussion, and no shareholder voting information. It is a regulatory update to the stock exchanges about a compliance matter. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-11-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated November 7, 2023, addressed to stock exchanges regarding the schedule of an Analyst/Institutional Investor Meeting. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which governs disclosure of material events. The content is purely an announcement of a meeting schedule with no financial data, analysis, or report attached. The document length is only 1541 characters, indicating it is a brief announcement rather than a detailed report or presentation. Therefore, it fits the category of Investor Presentation (IP) related announcements or scheduling. However, since it only announces the schedule of meetings and does not contain the presentation itself, it is best classified as a Regulatory Filing (RNS) as a general regulatory announcement about investor meetings, not the presentation or report itself.
2023-11-07 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding a newspaper advertisement of the company's unaudited financial results for Q2 FY24. It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates publication of financial results in newspapers. The document includes the advertisement copies but does not contain the full financial report or detailed financial statements. The document length is short (1822 characters), and it serves as an announcement or notification rather than the actual financial report. Therefore, it fits best as a Regulatory Filing (RNS) since it is a regulatory announcement about the publication of financial results, not the results themselves or a detailed interim report.
2023-11-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short communication dated November 6, 2023, addressed to stock exchanges regarding an earnings call held for the quarter and half year ended September 30, 2023. It states that the audio recording of the earnings call has been uploaded on the company's website and provides a weblink. The document does not contain the transcript or detailed financial data but is an announcement about the availability of the earnings call recording. Given the short length (1383 characters) and the nature of the content (announcement of call recording availability), this fits the category of a Call Transcript (CT) related announcement. However, since it only announces the recording and does not provide the transcript text itself, it is best classified as a Regulatory Filing (RNS) as a general announcement. But the filing definitions specify that Call Transcript (CT) is for full text transcripts, and this is only an announcement of the recording. Therefore, the best fit is Regulatory Filings (RNS).
2023-11-06 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated November 6, 2023, announcing the Q2FY24 financial results of Gland Pharma Limited. It includes detailed consolidated and segment financial data for the quarter and half-year ended September 30, 2023, with revenue, profit, margins, and other financial metrics. The document also mentions an upcoming earnings call to discuss these results. The content is typical of an Earnings Release, which provides key highlights of quarterly financial performance but is not a full interim or annual report. The document length (10,307 characters) and detailed financial summary support this classification. There is no indication that this is a full Annual Report (10-K), Interim Report (IR), or Management Discussion & Analysis (MDA). It is not a regulatory filing or announcement of a report publication but the actual earnings announcement. Therefore, the appropriate classification is Earnings Release (ER). Q2 2024
2023-11-06 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is an investor presentation dated November 6, 2023, regarding Q2 FY24 financial results of Gland Pharma Limited. It includes detailed financial highlights such as revenue, EBITDA, PAT, margins, segment performance, and operational commentary. The text explicitly states it is an "Investor Presentation on Q2FY24 Financial Results" and contains forward-looking statements, financial metrics, and business updates typical of investor presentations. It is not a full annual or quarterly report, nor an earnings release summary, but a detailed presentation aimed at investors. The document is about 15,000 characters long, containing substantive financial data and analysis, consistent with the definition of an Investor Presentation (IP).
2023-11-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.